CAMP4 grants options for 43,000 shares to new hires

Granted April 15, the options carry a 10-year term and vest over four years, tying pay to continued service.

Apr. 17, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of stock certificates, a pen, and a calculator arranged on a clean white background, symbolizing the financial tools used to attract and retain employees in the biotech industry.A minimalist still life captures the financial instruments and tools used to incentivize and retain top talent in the biotech industry.Cambridge Today

CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, announced that on April 15, 2026, the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company's common stock to three newly hired employees. The options have a ten-year term and an exercise price per share of $4.59, which is equal to the closing price of CAMP4's common stock as of the Grant Date. The options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee's continued service with CAMP4 through the applicable vesting dates.

Why it matters

The inducement grants are a common practice in the biopharmaceutical industry to attract and retain top talent. By tying the vesting of the options to continued service, CAMP4 is incentivizing the new hires to remain with the company and contribute to its long-term success.

The details

The Inducement Grants were granted in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to grant stock options as inducements to new employees without shareholder approval. The options have a 10-year term and an exercise price of $4.59 per share, which matches the closing price of CAMP4's stock on the grant date.

  • The Inducement Grants were granted on April 15, 2026.

The players

CAMP4 Therapeutics Corporation

A clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases.

Compensation Committee

The committee of CAMP4's Board of Directors that is responsible for granting the inducement stock options to the new hires.

Got photos? Submit your photos here. ›

The takeaway

The inducement grants demonstrate CAMP4's commitment to attracting and retaining top talent in the highly competitive biopharmaceutical industry. By aligning the new hires' compensation with the company's long-term success, CAMP4 is positioning itself for continued growth and innovation in the development of treatments for genetic diseases.